<DOC>
	<DOCNO>NCT00108758</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , South America , United States America ( USA ) . The purpose study evaluate effectiveness secondary prophylactic treatment NovoSeven® haemophilia A B patient inhibitor .</brief_summary>
	<brief_title>Efficacy NovoSeven® Bleeding Prophylaxis Hemophilia</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosis congenital haemophilia A B inhibitor development FVIII FIX , respectively Prophylactic administration haemostatic drug within 3 last month prior enter trial .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>